Ayahuasca: Chemical Description, Medicinal Uses, and Its Role in the 2030 Agenda

Document prepared for educational and scientific dissemination purposes.

Authors: Fundación Chinchilejo EIN: 93-2687815

Date: 7/25/2025

Introduction

Ayahuasca, a traditional psychedelic decoction used by indigenous peoples of the Amazon, has gained scientific attention for its potential therapeutic applications. Composed primarily of Banisteriopsis caapi and Psychotria viridis, its ceremonial use dates back centuries. Today, it is being studied at renowned universities such as Harvard and Cambridge for its effects on mental health. This article explores its chemical composition, medically supported benefits, contraindications, and how its promotion aligns with the United Nations’ Sustainable Development Goals (SDGs) of the 2030 Agenda.

Chemical Description of Ayahuasca

Ayahuasca contains two main components:

• Harmalines (β-carbolines):
  • Found in B. caapi, they inhibit monoamine oxidase (MAO), allowing DMT to be active when taken orally.
  • Include harmine, harmaline, and tetrahydroharmine, which have neuroprotective and antidepressant effects (Dos Santos et al., 2017).
• Dimethyltryptamine (DMT):
  • Present in P. viridis, it is a potent serotonergic agonist (5-HT2A) linked to altered states of consciousness (Palhano-Fontes et al., 2019).

Table 1: Main Active Components of Ayahuasca

Compound	Source	Pharmacological Effect
Workshops	Banisteriopsis caapi	MAO inhibitor, antidepressant
Construction	Psychotria viridis	Psychedelic, serotonergic modulator

Medicinal Uses Supported by Research

Clinical and preclinical studies highlight its potential in:

1. Mental Health
   • Treatment-Resistant Depression (TRD):
     • A pivotal study published by Cambridge University Press (2018) showed that a single dose of ayahuasca produced significant improvements within 24–48 hours in TRD patients compared to placebo (p < 0.05). Effects lasted up to 7 days post-administration (Palhano-Fontes et al., 2018).
     • Proposed mechanism: Modulation of the default mode network (DMN) and increased synaptic plasticity (Include comparative graphic vs. placebo).
   • Post-Traumatic Stress Disorder (PTSD):
     • Research in Canada suggests it facilitates emotional reprocessing (Gorman et al., 2021).
2. Neuroprotection
   • β-carbolines promote neurogenesis and reduce brain inflammation (Frecska et al., 2016).

Infographic 1: Mechanism of antidepressant action of ayahuasca
[Include graphic on serotonergic modulation and effects on neural networks]

Contraindications and Risks

Despite its benefits, ayahuasca carries risks:

• Drug interactions: Contraindicated with SSRIs, MAOIs, and sympathomimetic drugs due to the risk of serotonin syndrome.
• Latent psychosis: May exacerbate undiagnosed psychiatric disorders (Szmulewicz et al., 2020).
• Safe context: Recreational use or use without expert guidance increases cardiovascular and psychological risks.

Ayahuasca and the UN 2030 Agenda

Promoting traditional indigenous ceremonies contributes to:

• SDG 3 (Health and Well-being): Integration of ancestral medicine into healthcare systems.
• SDG 10 (Reduced Inequalities): Economic empowerment of indigenous communities.
• SDG 15 (Life on Land): Conservation of Amazonian biodiversity through sustainable practices.

Conclusion

Ayahuasca represents a bridge between ancestral knowledge and modern science, with promising applications in psychiatry. Ethical regulation and respect for indigenous traditions are key to maximizing benefits and minimizing risks, aligning with the SDGs.

Academic Bibliography

1. Dos Santos, R. G., et al. (2017). “Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness”. Current Neuropharmacology.
2. Palhano-Fontes, F., et al. (2018). “Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial”. Psychological Medicine, Cambridge University Press. DOI: [Insert DOI].
3. Sanches, R. F., et al. (2016). “Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression”. Revista Brasileira de Psiquiatria.
4. Gorman, I., et al. (2021). “Psychedelic Harm Reduction and Integration in PTSD Treatment”. Frontiers in Pharmacology.
5. Frecska, E., et al. (2016). “The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization”. Frontiers in Pharmacology.

Note: For detailed infographics and tables, consult the original studies or contact Fundación Chinchilejo (https://chinchilejo.org/).

Document prepared for educational and scientific dissemination purposes.

Appendix: Relevant Clinical Studies

1. Palhano-Fontes et al. (2018)
   • Double-blind trial with *n = 29* TRD patients.
   • Key results:
     • 50% reduction in MADRS (depression scale) in 64% of the ayahuasca group vs. 27% in placebo.
     • Mild side effects (nausea, vertigo).
2. Harvard University
   • Neuroimaging studies (2019): Ayahuasca modulates DMN connectivity, similar to psilocybin (Pasquini et al., 2019).
   • Systematic review (2020): Harmine has potential as a rapid-acting antidepressant (Dos Santos et al., 2020).
   • Collaboration with Brazil (2021): Ayahuasca stimulates neurogenesis and synaptic plasticity (Oliveira-Lima et al., 2021).
3. University of Cambridge
   • Key study (2018): Ayahuasca showed rapid antidepressant effects in TRD (Palhano-Fontes et al., 2018).
   • Long-term safety (2019): Sustained improvements in depressive symptoms up to 6 months post-treatment (Sanches et al., 2019).

Note: For access to studies, visit Harvard Catalyst or PubMed.